
FDA and EMA accept review of JAK3/TEC inhibitor ritlecitinib
On September 19, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the oral JAK3/TEC
On September 19, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the oral JAK3/TEC